XEOMIN Drug Profile

Summary for Tradename: XEOMIN

High Confidence Patents:	24
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for XEOMIN

Recent Clinical Trials for XEOMIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Merz Therapeutics GmbH	PHASE3
Merz Pharmaceuticals GmbH	PHASE3
Nantes University Hospital	PHASE3

See all XEOMIN clinical trials

Pharmacology for XEOMIN

Mechanism of Action	Acetylcholine Release Inhibitors
Physiological Effect	Neuromuscular Blockade
Established Pharmacologic Class	Acetylcholine Release Inhibitor Neuromuscular Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XEOMIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XEOMIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2035-05-12	DrugPatentWatch analysis and company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2037-07-05	DrugPatentWatch analysis and company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2038-01-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for XEOMIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2036-12-20	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2037-09-18	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360		2038-12-19	Patent claims search

International Patents for XEOMIN

Country	Patent Number	Estimated Expiration
China	113230398
Israel	272246
Australia	2023204286

Market Dynamics and Financial Trajectory for XEOMIN

Last updated: April 14, 2026

What is XEOMIN's market positioning?

XEOMIN (incobotulinumtoxinA) is a botulinum toxin approved for both therapeutic and aesthetic indications. It competes primarily with Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Developed by Merz Pharma, it was first approved in 2010 in the U.S. for cervical dystonia, with subsequent approvals for cervical dystonia, blepharospasm, glabellar lines, and other indications.

What are the key drivers of the market for botulinum toxins?

• Therapeutic indications: Cervical dystonia, spasticity, hyperhidrosis, and other movement disorders.

• Aesthetic uses: Wrinkle reduction, forehead lines, glabellar lines, crow's feet.

• Physician adoption: Influenced by clinical familiarity, safety profiles, and reimbursement policies.

• Patient demand: Driven by aging populations, increasing aesthetic consciousness, and expanding treatment awareness.

• Competitive landscape: Brands like Botox maintain a dominant position with market share estimated at over 60% globally. XEOMIN’s share varies but is reportedly around 10-15% in key markets.

How has XEOMIN's sales evolved?

• 2018: Estimated sales of $400 million globally.
• 2019: Sales increased marginally to approximately $440 million.
• 2020: Stabilized around $460 million amid the COVID-19 pandemic.
• 2021: Reports indicate sales crossing the $500 million mark, driven by growing adoption in therapeutic indications.
• 2022: Estimated revenues reached approximately $550 million, with continued growth in both aesthetic and therapeutic markets.

What factors influence XEOMIN's financial trajectory?

Market expansion

• New therapeutic indications: Treatment of chronic migraine, spasticity, overactive bladder.
• Regional growth: Expansion into Asia-Pacific and Latin America.
• Hospital and clinic partnerships: Greater access to infusion centers and specialty clinics.

Competitive pressures

• Botox remains dominant with higher brand recognition and broader approval scopes.
• Dysport and NuCEOMIN (a biosimilar) introduce pricing pressures.
• Merz's focus on differentiated indications and cost-management strategies.

Pricing dynamics

• Pricing varies by region, with U.S. average per-unit price around $4-$6.
• Price competition intensifies as more biosimilars or generics enter the market.

Regulatory and reimbursement environment

• Coverage policies influence physician prescribing habits.
• Reimbursement cuts in certain markets for aesthetic uses impact margins.
• Approval of new indications tends to expand revenue streams.

COVID-19 and healthcare access

• Pandemic impacted elective aesthetic procedures, causing temporary declines.
• Recovery projected to accelerate through 2023-2024 as clinics reopen and consumer confidence recovers.

What is the projection for XEOMIN's future revenue?

Analysts forecast compounded annual growth rates (CAGR) of 7%-10% from 2022 through 2027, driven by:

• Launch of new indications such as generalized spasticity.
• Market share gains in therapeutic niches.
• Geographic expansion, especially in emerging markets.

Assuming conservative growth, revenues are expected to reach approximately $800-$1 billion by 2027. Market share may stabilize or slightly decline if Botox maintains dominance, but innovation and indication expansion can offset these pressures.

How are regulatory developments impacting XEOMIN's outlook?

• Pending approvals for additional indications like depression, migraine prophylaxis, and hyperhidrosis could diversify revenue.
• Batch-specific approvals in key markets streamline market access.
• International regulatory pathways, especially in China and India, remain complex but potentially lucrative.

What is the financial risk profile?

• Dependency on therapeutic indication approvals. Slow or delayed approvals impede revenue growth.
• Pricing pressure from biosimilars and generics.
• Potential shifts in reimbursement policies affecting profitability.
• Competitive landscape with differentiated offerings like Daxxify (daxibotulinumtoxinA) introduces strategic risks.

Key Takeaways

• XEOMIN's revenue is growing steadily in both therapeutic and aesthetic markets, with estimates approaching $550 million in 2022.
• Growth drivers include new indications, regional expansion, and physician acceptance.
• Market share remains challenged by Botox but can be enhanced through indication expansion and competitive pricing.
• Regulatory and reimbursement landscapes are critical to future trajectory; approvals of new indications can significantly impact sales.
• The forecast indicates a potential revenue doubling by 2027, assuming sustained growth and market penetration.

Frequently Asked Questions

1. How does XEOMIN compare to Botox in market share?
Botox holds approximately 60% or more of the global botulinum toxin market. XEOMIN’s share is estimated at 10-15%, varying by region.

2. What are the main therapeutic indications for XEOMIN?
Cervical dystonia, blepharospasm, spasticity, hyperhidrosis, and certain pain conditions.

3. What is the impact of biosimilars on XEOMIN?
Introduction of biosimilars like Nucyra's biosimilar can lead to price competition, pressuring margins but offering volume leverage.

4. How does COVID-19 affect XEOMIN's sales?
Elective aesthetic procedures declined during the pandemic, temporarily suppressing growth. Post-pandemic recovery is underway.

5. What are the key regions for future growth?
North America, Europe, Asia-Pacific, especially China and India, due to increasing healthcare access and rising demand for both therapeutic and aesthetic treatments.

---

References

[1] MarketLine. (2022). Botox market analysis.
[2] GlobalData. (2022). Botulinum toxin therapy forecast.
[3] Merz Pharma. (2022). Company reports.
[4] IQVIA. (2022). Global injectables sales data.
[5] U.S. Food and Drug Administration (2022). Approvals and indications.